Publications

> Go to Finkbeiner Publications on PubMed

Original Articles (peer reviewed)

  1. Arrasate M, Finkbeiner S. Protein aggregates in Huntington’s disease. Exp. Neurol., in press.
  2. Wray S, Self M, Lewis PA, Taanman J-W, Ryan N, Mahoney C, Devine MJ, Sheerin UM, Houlden H, Morris H, Healy D, Marti-Masso J-F, Sutherland M, Shapira AJ, Uitti RJ, Guttman M, Opala G, Jasinska-Myga B, Puschmann A, Nilsson C, Guttmann L, Boeve B, Boylan K, Stoessl J, Gerpen JV, Gerstenhaber M, Gwinn K, Dawson T, Isacson O, Marder K, Przedborski S, Finkbeiner S, Rothstein JD, Wszolek Z, Rossor M, Hardy J. Creation of an open-access mutation-defined fibroblast resource for neurological disease research. PLoS One, in press.
  3. Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, Phatnani HP, Puddifoot CA, Story D, Fletcher J, Park IH, Friedman BA, Daley GQ, Wyllie DJ, Hardingham GE, Wilmut I, Finkbeiner S, Maniatis T, Shaw CE, Chandran S. (2012) Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. USA109:5803–5808.
  4. Nucifora LG, Burke KA, Feng X, Arbez N, Zhu S, Miller J, Yang G, Ratovitski T, Delannoy M, Muchowski PJ, Finkbeiner S, Legleiter J, Ross CA, Poirier MA. (2012) Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein. J. Biol. Chem. 287:16017–16028.
  5. Sharma P, Ando DM, Daub A, Kaye JA, Finkbeiner S. (2012) High-throughput screening in primary neurons. Meth. Enzymol. 506:331–360.
  6. Korb E, Finkbeiner S. (2011). Arc in synaptic plasticity: from gene to behavior. Trends Neurosci. 34:591–598.
  7. Gittis AH, Hang GB, LaDow ES, Shoenfeld LR, Atallah BV, Finkbeiner S, Kreitzer AC. (2011). Rapid target-specific remodeling of fast-spiking inhibitory circuits after loss of dopamine. Neuron 71:858–868.
  8. Miller J*, Arrasate M*, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, Osmand A, Gray M, Thulasiramin V, Saudou F, Segal M, Yang XW, Masliah E, Thompson LM, Muchowski P, Weisgraber K, Finkbeiner S. (2011) Identifying polyglutamine protein species in situ that beat predict neurodegeneration. Nat. Chem. Biol. 7:925–934. (*Authors contributed equally to this work.)
  9. Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Edwards RH. (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein α-synuclein. J. Biol. Chem. 286:20710–20726.
  10. Skibinski G, Finkbeiner S. (2011) Drug discovery in Parkinson's disease–Updates and developments in the use of cellular models.Int. J. High Throughput Screen. 2:15–25.
  11. Zhang QC, Yeh T-L, Levya A, Frank LG, Miller J, Kim YE, Langen R, Finkbeiner S, Amzel ML, Ross CA, Poirier MA. (2011) A compact β model of huntingtin toxicity. J. Biol. Chem. 286:8188–8196.
  12. Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner, S. (2010). A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc. Natl. Acad. Sci. U.S.A. 107:16982–16987.
  13. Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S. (2010) Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into Huntington’s disease molecular pathogenesis. J. Neurosci. 30:10541–10550.
  14. Ramdzan Y, Nisbet RM, Miller J, Finkbeiner S, Hill AF, Hatters DM. (2010) Conformation sensors that distinguish monomeric proteins from oligomers in live cells. Chem. Biol. 17:371–379.
  15. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates G. (2010) Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 285:8808–8823.
  16. Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, Paganetti P, Muchowski PJ, Wilson S, Bates GP. (2010) Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Hum. Mol. Genet.19:65–78.
  17. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. (2010) Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30:639–649.
  18. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L. (2010) Tau reduction prevents Abeta-induced defects in axonal transport. Science 330:198.
  19. Finkbeiner S. (2010). Bridging the Valley of Death of therapeutics for neurodegeneration. Nat. Med. 16:1227–1232.
  20. Peebles CL, Yoo J, Thwin MT, Palop JJ, Noebels JL, Finkbeiner S. (2010) Arc regulates spine morphology and maintains network stability in vivo. Proc. Natl. Acad. Sci. USA 107:18173–18178.
  21. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW. (2009) Serines 13 and 16 are critical determinants of full–length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64:828–840.
  22. Thompson LM, Aiken CT, Agrawal N, Kaltenbach LS, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Lukacsovich T, Zhu Y-Z, Lau AL, Massey A, Hayden MR, Zeitlin SO, Finkbeiner S, Huang L, Lo DC, Patterson PH, Cuervo AM, Marsh JL, and Steffan JS. (2009) IKK phosphorylates huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187:1083–1099.
  23. Daub A, Sharma P, Finkbeiner S. (2009) High-content screening in primary neurons: Ready for prime time. Curr. Opin. Neurobiol. 19:537–543.
  24. Pintchovski SA, Peebles CL, Kim HJ, Verdin E, Finkbeiner S. (2009) The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. J. Neurosci. 29:1525–1537.
  25. Mitra S, Tsvetkov A, Finkbeiner S. (2009) Single neuron ubiquitin-proteasome dynamics accompanying inclusion body formation in Huntington disease. J. Biol. Chem. 284:4398–4403.
  26. Legleiter J, Lotz GP, Miller J, Ko J, Ng C, Williams GL, Finkbeiner S, Patterson PH, Muchowski PJ. (2009) Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment. J. Biol. Chem. 284:21647–21658.
  27. Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, Finkbeiner S, Merry DE. (2009) Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Gen. 18:1937–1950.
  28. Mitra S, Tsvetkov, AS, Finkbeiner S. (2009) Protein turnover and inclusion body formation. Autophagy 5:1037–1038.
  29. Finkbeiner S, Mitra S. (2008) The ubiquitination-proteasome pathway in Huntington’s disease. ScientificWorldJournal 8:421–433.
  30. Palop JJ, Chin J, Roberson ED, Wang J, Twin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron 55:697–711.
  31. Rao V, Carter S, Finkbeiner S. (2007) NMDA and AMPA receptors: Old channels, new tricks. Trends Neurosci. 30:284–291.
  32. Finkbeiner S, Cuervo AM, Morimoto RI, Muchowski PJ. (2006) Disease-modifying pathways in neurodegeneration. J. Neurosci. 26:10349–10357.
  33. Rao VR, Pintchovski SA, Peebles, CL, Mitra S, Finkbeiner S. (2006) AMPA receptors regulate transcription of the plasticity-related immediate early geneArc. Nat. Neurosci. 9:887–895.
  34. Bradley J, Rao VR, Wang J, Carter S, Finkbeiner S. (2006) Splice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression. J. Neurosci. 26:1065–1076.
  35. Peters-Libeu C, Newhouse Y, Krishnan P, Cheung K, Brooks E, Weisgraber K, Finkbeiner S. (2005) Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches.Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun. 61:1065–1068.
  36. Arrasate M, Finkbeiner S. (2005) Automated microscope system for determining factors that predict neuronal fate. Proc. Natl. Acad. Sci. USA 102:3840–3845.
  37. Arrasate M, Mitra S, Schweitzer E, Segal M, Finkbeiner S. (2004) Inclusion body formation reduces the levels of mutant huntingtin and the risk of neuronal death. Nature 431:805–810.
  38. Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington’s disease and involves huntingtin phosphorylation by Akt.Dev. Cell 2:831–837.
  39. Bradley J, Finkbeiner S. (2002) An evaluation of specificity in activity-dependent gene expression in neurons. Prog. Neurobiol. 67:469–477.
  40. Finkbeiner S. (2001) New roles for introns: Sites of combinatorial regulation of Ca2+-and cyclic AMP-dependent gene transcription.Sci. STKE 94:PE1–PE4.
  41. Finkbeiner S. (2000) CREB couples neurotrophin signals to survival messages. Neuron 25:11–14.
  42. Saudou F, Finkbeiner S, Devys D, Greenberg ME. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55–66.
  43. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20:709–726.
  44. Finkbeiner S, Greenberg ME. (1998) Ca2+ channel-regulated neuronal gene expression. J. Neurobiol. 37:171–189.
  45. Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. (1997) CREB: A major mediator of neuronal neurotrophin responses. Neuron 19:1031–1047.
  46. Finkbeiner S, Greenberg ME. (1996) Ca2+-dependent routes to Ras: Mechanisms for neuronal survival, differentiation, and plasticity? Neuron 16:233–236.
  47. van den Pol AN, Finkbeiner SM, Cornell-Bell AH. (1992) Calcium excitability and oscillations in suprachiasmatic nucleus neurons and gliain vitro. J. Neurosci.12:2648–2664.
  48. Finkbeiner S. (1992) Calcium waves in astrocytes-filling in the gaps. Neuron 8:1101ñ1108.
  49. Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ. (1990) Glutamate induces calcium waves in cultured astrocytes: Long-range glial signaling. Science 247:470–473.
  50. Keana JF, McBurney RN, Scherz MW, Fischer JB, Hamilton PN, Smith SM, Server AC, Finkbeiner S, Stevens CF, Jahr C, Weber E. (1989) Synthesis and characterization of a series of diarylguanidines that are noncompetitiveN-methyl-D-aspartate receptor antagonists with neuroprotective properties. Proc. Natl. Acad. Sci. USA86:5631–5635.
  51. Finkbeiner S, Stevens CF. (1988) Applications of quantitative measurements for assessing glutamate neurotoxicity. Proc. Natl. Acad. Sci. USA 85:4071–4074.

Commentaries, Review Articles, Chapters and Other Publications

  1. Finkbeiner S. Combining automated microscopy with statistics. In: Physical Cell Biology: Closing the Gap. Eds. Brown WE, Howard, GC. New York: Oxford University Press, solicited, in press.
  2. Finkbeiner S. Predicting fates in models of neurodegenerative disease: Longitudinal measures of protein homeostasis in live neurons. In: Protein Quality Control in Neurodegenerative Diseases.Eds; Morimoto RI, Christensen YS. Berlin, Springer-Verlag Press, in press.
  3. Elia L, Finkbeiner S. High-throughput RNA interference as a tool for discovery. In: Physical Cell Biology: Closing the Gap. OMICs in Neuroscience.Ed; Coppola G. New York, Oxford University Press, solicted, in press.
  4. Finkbeiner S. (2011) Huntington’s disease. In: The Chemistry and Biology of Diseases of Protein Conformation. Eds. Morimoto RI, Kelly JW, Selkoe DJ. The Cold Spring Harbor Perspectives in Biology Series. New York, Cold Spring Harbor Press, pp. a007476.
  5. Klionsky DJ, Baehrecke EH, Brumell JH, Chu CT, Codogno P, Cuervo AM, Debnath J, Deretic V, Elazar Z, Eskelinen L, Finkbeiner S, Fueyo-Margareto J, Gewirtz D, Jäättelä M, Kroemer G, Levine B, Melia TA, Mizushima N, Rubinsztein DC, Simonsen A, Thorburn A, Thumm M, Tooze SA. (2011) A comprehensive glossary of autophagy-related molecules and processes (2nd Edition).Autophagy7:1273–1294.
  6. Barmada SJ, Finkbeiner S. (2010) Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: Disease-associated pathways. Rev. Neurosci. 21:251–272
  7. Barmada S, Finkbeiner S. (2010) Bringing SOD1 into the fold. Nat. Neurosci.13:1303–1304.
  8. Kratter IH, Finkbeiner S. (2010) PolyQ disease: Too many Q’s, too much function? Neuron 67:897–899.
  9. Peebles CL, Finkbeiner S. (2007) RNA back in play. Nat. Neurosci.10:1083–1084.
  10. Beal FM, Bossy-Wetzel E, Finkbeiner S, Fiskum G, Glasson B, Johnson C, Khachaturian ZS, Lee VMY, Nicholls D, Reddy H, Reynolds I, Teplow DB, Thal LJ, Trojanowski JQ, Walsh DM, Wetzel R, Wexler NS, Young AB, Bain L. (2006) Common threads in neurodegenerative disorders of aging. Alzheimers Dement. 2:263–334.
  11. Brooks L, Arrasate, M, Cheung K, Finkbeiner S. (2004) Using antibodies to analyze polyglutamine stretches. In: Methods in Molecular Biology: Triplet Repeat Protocols.Ed. Kohwi Y. Totowa: Humana Press, pp. 277:103–128.
  12. Rao VR, Finkbeiner S. (2003) Secrets of a secretase: N-cadherin proteolysis regulates CBP function. Cell 144:533–535.
  13. Finkbeiner S. (2000) Calcium regulation of the brain-derived neurotrophic factor gene. Cell. Mol. Life Sci.57:394–401.
  14. Curtis J, Finkbeiner S. (1999) Sending signals from the synapse to the nucleus: Possible roles for CaMK, Ras/ERK, and SAPK pathways in the regulation of synaptic plasticity and neuronal growth. J. Neurosci. Res.58:88–95.
  15. Finkbeiner S, Dalva MB. (1998) To fear or not to fear: What was the question? A potential role for Ras-GRF in memory. Bioessays 20:691–695.
  16. Finkbeiner SM, Greenberg ME. (1998) Ca2+-regulated neuronal gene expression. J. Neurobiol. 37:171–189.
  17. Finkbeiner S, Greenberg ME. (1997) Spatial features of calcium-regulated gene expression. Bioessays 19:657–660.
  18. Finkbeiner SM. (1996) Neurotrophins and the synapse. Neuroscientist 2:139–142.
  19. Finkbeiner SM. (1996) Calcium control and modulation. In: Neuroglial Cells. Eds., Kettenmann H, Ransom B. New York: Oxford University Press, pp. 273–288.
  20. Finkbeiner SM. (1995) Calcium-mediated gene expression: Mechanism for neuronal plasticity and survival. Neuroscientist 1:317–320.
  21. Finkbeiner SM. (1993) Glial calcium. Glia 9:83–104.
  22. Cornell-Bell AH, Finkbeiner SM, Cooper MS, Smith SJ. (1992) Extraneuronal communication. In: Encyclopedia of Neuroscience: Neuroscience Year. Supplement 2. Boston: Birkhauser, pp. 65–68.
  23. Cornell-Bell AH, Finkbeiner SM. (1991) Ca2+ waves in astrocytes. Cell Calcium 12:185–204.
  24. Renzi R, Finkbeiner S. (1991) Ciprofloxacin interaction with sodium warfarin: A potentially dangerous side effect. Am. J. Emerg. Med. 9:551–552.
  25. Goldman RS, Finkbeiner SM, Smith SJ. (1991) Endothelin induces a sustained rise in intracellular calcium in hippocampal astrocytes. Neurosci. Lett.123:4–8.